Tigis

AVN 2/2026
AVN 2/2026

Obsah

Editorial .................................................................................................... 33

Obsah .......................................................................................................... 35

Přehledné články

Vitamin D a VDR aktivátory – novinky v prevenci
a léčbě sekundární hyperparathyreózy
Sylvie Dusilová Sulková, Vladimír Palička .................................................. 38

Vitamin D – imunomodulační hormon
Jiřina Bartůňková ....................................................................................... 46

 Preimplantační genetické testování u pacientů s ADPKD
Pavel Navrátil, Pavel Navrátil, Jan Diblík,
Kateřina Sobolová, Veronika Sabolová,
Jitka Štekrová, Jiří Doležal ......................................................................... 52

Rozhovor

MUDr. Jana Lachmanová ........................................................................... 59

Předplatné ................................................................................................ 63

Pokyny autorům ....................................................................................... 64

 

CONTENTS

Editorial .................................................................................................... 33

Contents ................................................................................................... 35

Reviews

Vitamin D and VDR activators – new developments
in the prevention and treatment of secondary hyperparathyroidism
Sylvie Dusilová Sulková, Vladimír Palička ................................................... 38

Vitamin D – an immunomodulatory hormone
Jiřina Bartůňková ........................................................................................ 46

Preimplantation genetic testing in patients with ADPKD
Pavel Navrátil, Pavel Navrátil, Jan Diblík, Kateřina Sobolová,
Veronika Sabolová, 
Jitka Štekrová, Jiří Doležal ........................................... 52

Interview

MUDr. Jana Lachmanová ............................................................................ 59

Subscription ............................................................................................... 63

Instruction for authors ............................................................................... 64